126 related articles for article (PubMed ID: 30744934)
1. Can We Discharge Dynamically Risk-Stratified Low-Risk (Excellent Response to Treatment) Thyroid Cancer Patients After 5 Years of Follow-Up?
Seejore K; Gerrard GE; Gill VM; Murray RD
Clin Oncol (R Coll Radiol); 2019 Apr; 31(4):219-224. PubMed ID: 30744934
[TBL] [Abstract][Full Text] [Related]
2. Outcomes of 756 patients with differentiated thyroid cancer and excellent response to treatment: An evidence-based paradigm for long-term surveillance strategies.
Seejore K; Mulla O; Gerrard GE; Gill VM; Al-Qaissi A; Moor JW; Murray RD
Clin Endocrinol (Oxf); 2022 Mar; 96(3):395-401. PubMed ID: 34185343
[TBL] [Abstract][Full Text] [Related]
3. Follow-up of patients with thyroglobulin-antibodies: Rising Tg-Ab trend is a risk factor for recurrence of differentiated thyroid cancer.
de Meer SGA; Vorselaars WMCM; Kist JW; Stokkel MPM; de Keizer B; Valk GD; Borel Rinkes IHM; Vriens MR
Endocr Res; 2017 Nov; 42(4):302-310. PubMed ID: 28509618
[TBL] [Abstract][Full Text] [Related]
4. Neck Sonography and Suppressed Thyroglobulin Have High Sensitivity for Identifying Recurrent/Persistent Disease in Patients With Low-risk Thyroid Cancer Treated With Total Thyroidectomy and Radioactive Iodine Ablation, Making Stimulated Thyroglobulin Unnecessary.
Domínguez JM; Nilo F; Contreras T; Carmona R; Droppelmann N; González H; Iturrieta V; Tuttle RM
J Ultrasound Med; 2017 Nov; 36(11):2299-2307. PubMed ID: 28543974
[TBL] [Abstract][Full Text] [Related]
5. A Follow-Up Strategy for Patients with an Excellent Response to Initial Therapy for Differentiated Thyroid Carcinoma: Less Is Better.
Jeon MJ; Kim M; Park S; Oh HS; Kim TY; Kim WB; Shong YK; Kim WG
Thyroid; 2018 Feb; 28(2):187-192. PubMed ID: 29179642
[TBL] [Abstract][Full Text] [Related]
6. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
7. Stimulated thyroglobulin values above 5.6 ng/ml before radioactive iodine ablation treatment following levothyroxine withdrawal is associated with a 2.38-fold risk of relapse in Tg-ab negative subjects with differentiated thyroid cancer.
Mousa U; Yikilmaz AS; Nar A
Clin Transl Oncol; 2017 Aug; 19(8):1028-1034. PubMed ID: 28258491
[TBL] [Abstract][Full Text] [Related]
8. Unstimulated high sensitive thyroglobulin measurement predicts outcome of differentiated thyroid carcinoma.
Giovanella L; Maffioli M; Ceriani L; De Palma D; Spriano G
Clin Chem Lab Med; 2009; 47(8):1001-4. PubMed ID: 19589104
[TBL] [Abstract][Full Text] [Related]
9. Risk factors and stratification for recurrence of patients with differentiated thyroid cancer, elevated thyroglobulin and negative I-131 whole-body scan, by restaging
Okuyucu K; Ince S; Alagoz E; Emer O; San H; Balkan E; Ayan A; Meric C; Haymana C; Acıkel C; Gunalp B; Karacalioglu AO; Arslan N
Hell J Nucl Med; 2016; 19(3):208-217. PubMed ID: 27824959
[TBL] [Abstract][Full Text] [Related]
10. Can the follow-up of patients with papillary thyroid carcinoma of low and intermediate risk and excellent response to initial therapy be simplified using second-generation thyroglobulin assays?
Rosario PW; Mourão GF; Calsolari MR
Clin Endocrinol (Oxf); 2016 Oct; 85(4):596-601. PubMed ID: 26940991
[TBL] [Abstract][Full Text] [Related]
11. Clinical utility of an ultrasensitive thyroglobulin assay in the follow-up of patients with differentiated thyroid cancer: can the stimulation test be avoided in patients with an intermediate recurrence risk?
Flores-Rebollar A; Pérez-Díaz I; Lagunas-Bárcenas S; García-Martínez B; Rivera-Moscoso R; Fagundo-Sierra R
Acta Otorhinolaryngol Ital; 2018 Jun; 38(3):188-193. PubMed ID: 29984794
[TBL] [Abstract][Full Text] [Related]
12. Stimulated high serum thyroglobulin with negative whole body imaging do not warrant an aggressive diagnostic and therapeutic approach in differentiated thyroid cancer patients: A follow-up of 5 years or till recurrence.
Gupta M; Choudhury PS; Nag S; Gupta P
Hell J Nucl Med; 2015; 18(3):207-14. PubMed ID: 26574692
[TBL] [Abstract][Full Text] [Related]
13. Dynamic Risk Stratification in the Follow-Up of Children and Adolescents with Differentiated Thyroid Cancer.
Zanella AB; Scheffel RS; Nava CF; Golbert L; Laurini de Souza Meyer E; Punales M; Gonçalves I; Dora JM; Maia AL
Thyroid; 2018 Oct; 28(10):1285-1292. PubMed ID: 30129889
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcome of low-risk differentiated thyroid cancer patients after radioiodine remnant ablation and recombinant human thyroid-stimulating hormone preparation.
Vianello F; Mazzarotto R; Mian C; Lora O; Saladini G; Servodio O; Basso M; Pennelli G; Pelizzo MR; Sotti G
Clin Oncol (R Coll Radiol); 2012 Apr; 24(3):162-8. PubMed ID: 21411300
[TBL] [Abstract][Full Text] [Related]
15. Clinical importance of anti-thyroglobulin auto-antibodies in patients with differentiated thyroid carcinoma: comparison with 99mTc-MIBI scans.
Küçük ON; Aras G; Kulak HA; Ibiş E
Nucl Med Commun; 2006 Nov; 27(11):873-6. PubMed ID: 17021427
[TBL] [Abstract][Full Text] [Related]
16. Follow-up of low-risk patients with differentiated thyroid carcinoma: a European perspective.
Schlumberger M; Berg G; Cohen O; Duntas L; Jamar F; Jarzab B; Limbert E; Lind P; Pacini F; Reiners C; Sánchez Franco F; Toft A; Wiersinga WM
Eur J Endocrinol; 2004 Feb; 150(2):105-12. PubMed ID: 14763906
[TBL] [Abstract][Full Text] [Related]
17. Papillary thyroid carcinoma patients assessed to be at low or intermediary risk after primary treatment are at greater risk of long term recurrence if they are thyroglobulin antibody positive or do not have distinctly low thyroglobulin at initial assessment.
Soyluk O; Boztepe H; Aral F; Alagol F; Özbey NC
Thyroid; 2011 Dec; 21(12):1301-8. PubMed ID: 22136265
[TBL] [Abstract][Full Text] [Related]
18. Non-suppressed thyrotropin and elevated thyroglobulin are independent predictors of recurrence in differentiated thyroid carcinoma.
Böhm J; Kosma VM; Eskelinen M; Hollmen S; Niskanen M; Tulla H; Alhava E; Niskanen L
Eur J Endocrinol; 1999 Nov; 141(5):460-7. PubMed ID: 10576761
[TBL] [Abstract][Full Text] [Related]
19. Papillary Thyroid Carcinoma Recurrence: Low Yield of Neck Ultrasound With an Undetectable Serum Thyroglobulin Level.
Epstein S; McEachern R; Khot R; Padia S; Patrie JT; Itri JN
J Ultrasound Med; 2018 Oct; 37(10):2325-2331. PubMed ID: 29498418
[TBL] [Abstract][Full Text] [Related]
20. Importance of postoperative stimulated thyroglobulin level at the time of 131I ablation therapy for differentiated thyroid cancer.
Hasbek Z; Turgut B; Kilicli F; Altuntas EE; Yucel B
Asian Pac J Cancer Prev; 2014; 15(6):2523-7. PubMed ID: 24761858
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
